NO961841L - Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater - Google Patents

Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater

Info

Publication number
NO961841L
NO961841L NO961841A NO961841A NO961841L NO 961841 L NO961841 L NO 961841L NO 961841 A NO961841 A NO 961841A NO 961841 A NO961841 A NO 961841A NO 961841 L NO961841 L NO 961841L
Authority
NO
Norway
Prior art keywords
conr5r6
pct
optionally substituted
alkyl
nr5r6
Prior art date
Application number
NO961841A
Other languages
English (en)
Norwegian (no)
Other versions
NO961841D0 (no
Inventor
John Christopher Danilewicz
David Ellis
Ryszard Jurek Kobylecki
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO961841D0 publication Critical patent/NO961841D0/no
Publication of NO961841L publication Critical patent/NO961841L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Treating Waste Gases (AREA)
  • Polyurethanes Or Polyureas (AREA)
NO961841A 1993-11-08 1996-05-07 Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater NO961841L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939322976A GB9322976D0 (en) 1993-11-08 1993-11-08 Therapeutic agents
PCT/EP1994/003509 WO1995013274A1 (en) 1993-11-08 1994-10-24 Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives

Publications (2)

Publication Number Publication Date
NO961841D0 NO961841D0 (no) 1996-05-07
NO961841L true NO961841L (no) 1996-05-07

Family

ID=10744811

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961841A NO961841L (no) 1993-11-08 1996-05-07 Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater

Country Status (25)

Country Link
US (2) US5750520A (de)
EP (1) EP0728132B1 (de)
JP (1) JP2739776B2 (de)
KR (1) KR960705807A (de)
CN (1) CN1134148A (de)
AT (1) ATE155464T1 (de)
AU (1) AU680565B2 (de)
CA (1) CA2176037C (de)
CO (1) CO4290420A1 (de)
CZ (1) CZ282359B6 (de)
DE (1) DE69404325T2 (de)
DK (1) DK0728132T3 (de)
ES (1) ES2105868T3 (de)
FI (1) FI112481B (de)
GB (1) GB9322976D0 (de)
GR (1) GR3024228T3 (de)
HU (1) HUT76268A (de)
IL (1) IL111478A0 (de)
NO (1) NO961841L (de)
NZ (1) NZ275798A (de)
PE (1) PE22795A1 (de)
PL (1) PL314237A1 (de)
SG (1) SG52218A1 (de)
WO (1) WO1995013274A1 (de)
ZA (1) ZA948772B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9522495D0 (en) * 1995-11-02 1996-01-03 Pfizer Ltd Therapeutic agents
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
EP1009758B1 (de) * 1997-08-29 2005-06-01 Tularik Limited Meta-benzamidinderivate als serinprotease-inhibitoren
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
AU9512298A (en) * 1997-09-30 1999-04-23 Molecular Design International, Inc. Beta3-adrenoreceptor agonists, agonist compositions and methods of using
DK0997474T3 (da) 1998-08-14 2004-02-09 Pfizer Antithrombotiske midler
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
SI20743A (sl) 2000-12-22 2002-06-30 Univerza V Ljubljani, Novi trombinski inhibitorji
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
SI21137A (sl) * 2002-01-24 2003-08-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Derivati azafenilalanina
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US7122580B2 (en) * 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
EP1636191A2 (de) 2003-06-17 2006-03-22 Arena Pharmaceuticals, Inc. Für die behandlung von mit dem 5ht2c rezeptor assoziierten krankheiten geeignete benzazepinderivative
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2005014533A2 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US20070275949A1 (en) * 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
NZ555981A (en) 2004-12-21 2011-01-28 Arena Pharm Inc Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
EP1833473B1 (de) 2004-12-23 2009-09-09 Arena Pharmaceuticals, Inc. 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0523539D0 (en) * 2005-11-18 2005-12-28 Lek Tovarna Farmacevtskih New use of organic compounds
CA2646044A1 (en) * 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
TWI389899B (zh) * 2006-08-08 2013-03-21 Msd Oss Bv 具口服活性之凝血酶抑制劑
CA2670285A1 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
PT2254881E (pt) * 2008-02-21 2012-12-10 Sanofi Sa Clorotiofeno-amidas como inibidores de factores de coagulação xa e da trombina
JP5422569B2 (ja) * 2008-02-21 2014-02-19 サノフイ 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
WO2009111004A1 (en) * 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
CN102648170A (zh) 2009-06-18 2012-08-22 艾尼纳制药公司 制备5-ht2c受体激动剂的方法
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
CN103189053A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 用于体重控制的5-ht2c激动剂的调节释放剂型
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
MX2013002418A (es) 2010-09-01 2013-08-01 Arena Pharm Inc Administracion de lorcaserina a individuos con daño renal.
BR112015007779A2 (pt) 2012-10-09 2017-07-04 Arena Pharm Inc célula de fluxo de permeabilidade e sistema de condutância hidráulica
WO2018213150A1 (en) 2017-05-15 2018-11-22 Mitobridge, Inc. Usp30 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503300A (ja) * 1990-11-15 1993-06-03 ペンタファルム　アクチェンゲゼルシャフト メタ置換フェニルアラニン誘導体

Also Published As

Publication number Publication date
PE22795A1 (es) 1995-08-15
EP0728132B1 (de) 1997-07-16
WO1995013274A1 (en) 1995-05-18
DK0728132T3 (da) 1997-09-01
CO4290420A1 (es) 1996-04-17
HU9601229D0 (en) 1996-07-29
AU680565B2 (en) 1997-07-31
JP2739776B2 (ja) 1998-04-15
CA2176037C (en) 1999-07-13
ES2105868T3 (es) 1997-10-16
NO961841D0 (no) 1996-05-07
DE69404325D1 (de) 1997-08-21
ZA948772B (en) 1996-05-07
US5861393A (en) 1999-01-19
SG52218A1 (en) 1998-09-28
PL314237A1 (en) 1996-09-02
FI961939A0 (fi) 1996-05-07
FI961939A (fi) 1996-05-07
JPH09500391A (ja) 1997-01-14
NZ275798A (en) 1997-09-22
ATE155464T1 (de) 1997-08-15
GB9322976D0 (en) 1994-01-05
AU8104994A (en) 1995-05-29
DE69404325T2 (de) 1997-10-30
GR3024228T3 (en) 1997-10-31
HUT76268A (en) 1997-07-28
CZ282359B6 (cs) 1997-07-16
EP0728132A1 (de) 1996-08-28
CZ132296A3 (en) 1996-08-14
US5750520A (en) 1998-05-12
CA2176037A1 (en) 1995-05-18
CN1134148A (zh) 1996-10-23
KR960705807A (ko) 1996-11-08
IL111478A0 (en) 1994-12-29
FI112481B (fi) 2003-12-15

Similar Documents

Publication Publication Date Title
DE69404325D1 (de) Antithrombotische amidinophenylalanin- und amidinopyridylalanin-derivate
GR3033070T3 (en) Antithrombotic amidinotetrahydropyridylalanine derivatives
DE60324183D1 (en) Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DE60221391D1 (de) Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
WO2005042533A3 (en) 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-iv inhibitors
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
ATE331709T1 (de) Substituierte 3-carbonyl-1-yl essigsäure derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
ATE261939T1 (de) Amidinoderivate und ihre verwendung als thrombin- inhibitoren
EP0645382A4 (de) Cumarin derivate und deren anwendung.
MX9708278A (es) Derivados de amidinotetrahidropiridilalanina, procedimiento para su preparacion y uso de los mismos.
MX9803498A (es) Derivados de n-amidino piperidina y benzamidina antitromboticos.
RS20050514A (en) Compounds having prolyl oligopeptidase inhibitory activity
EA200300059A1 (ru) Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина, таксанов и/или антиметаболитов
ECSP961723A (es) Derivados de amidinotetrahidropiridilalanina antitromboticos
KR950700897A (ko) 옥소-및 히드록시-치환된 탄화수소의 아민 유도체(Amine Derivatives of oxo- and hydroxy-substituted hydrocarbons)